Invention Grant
US5589486A N-hydroxyalkyl-substituted 1,2,3,6-tetrahydro-pyridine and piperidine
derivatives
失效
N-羟基烷基取代的1,2,3,6-四氢 - 吡啶和哌啶衍生物
- Patent Title: N-hydroxyalkyl-substituted 1,2,3,6-tetrahydro-pyridine and piperidine derivatives
- Patent Title (中): N-羟基烷基取代的1,2,3,6-四氢 - 吡啶和哌啶衍生物
-
Application No.: US244867Application Date: 1995-01-17
-
Publication No.: US5589486APublication Date: 1996-12-31
- Inventor: Kalman Harsanyi , Tibor Gizur , Eva Agai-Csongor , Anna Kallai-Sohonyai , Marta Kapolnas-Pap , Eva Csizer , Bela Heged us , Laszlo Szporny , Bela Kiss , Egon Karpati , Eva Palosi , Zsolt Szombathelyi , Adam Sarkadi , Aniko Gere , Mihaly Bodo , Katalin Csomor , Judit Laszy , Zsolt Szentirmai , Erzsebet Lapis , Sandor Szabo , Peter Bod , Attila Csehi
- Applicant: Kalman Harsanyi , Tibor Gizur , Eva Agai-Csongor , Anna Kallai-Sohonyai , Marta Kapolnas-Pap , Eva Csizer , Bela Heged us , Laszlo Szporny , Bela Kiss , Egon Karpati , Eva Palosi , Zsolt Szombathelyi , Adam Sarkadi , Aniko Gere , Mihaly Bodo , Katalin Csomor , Judit Laszy , Zsolt Szentirmai , Erzsebet Lapis , Sandor Szabo , Peter Bod , Attila Csehi
- Applicant Address: HUX Budapest
- Assignee: Richter Gedeon Vegyeszeti Gyar Rt.
- Current Assignee: Richter Gedeon Vegyeszeti Gyar Rt.
- Current Assignee Address: HUX Budapest
- Priority: HUX3747/91 19911202; HUX3747/91 19920609
- Main IPC: A61K31/44
- IPC: A61K31/44 ; A61K31/445 ; A61K31/451 ; A61P9/00 ; A61P9/08 ; A61P9/10 ; A61P25/28 ; C07D211/14 ; C07D211/18 ; C07D211/22 ; C07D211/52 ; C07D211/70
Abstract:
The invention relates to novel N-hydroxy-substituted 1,2,3,6-tetrahydropyridine and piperidine derivatives of the formula ##STR1## wherein A, B, D, E, G, I and R are as defined in the specification, m is 0, 1 or 2, with the proviso that:m is 0 or 2, or both G and I are hydrogen, when A is benzyl or halogen-monosubstituted benzyl group; andm is 1, when A is 2-picolyl, as well as their pharmaceutically acceptable acid addition salts. The compounds of formula (I) are useful for enhancing the tolerance of mammals (including man) against hypoxic and/or ischaemic states as well as for treating the degenerative and functional disturbances arising from hypoxic and/or ischaemic results.
Public/Granted literature
- US6161717A End closure with reverse bead on opening panel Public/Granted day:2000-12-19
Information query